Philadelphia, PA – The Biotechnology Industry Organization (BIO) released “Bioscience Economic Development in the States: Legislation and Job Creation Best Practices” today at the 2015 BIO International Convention. The Best Practices Guide is the bioscience industry’s leading comprehensive analysis of state legislative and regulatory initiatives in support of economic development.
New Brunswick, NJ - Johnson & Johnson Innovation said it has launched 17 collaborations with research institutions and healthcare companies, bringing to more than 200 the total number of collaborations formed since its 2013 launch.
Trenton, NJ - Continuing its commitment to providing resources to emerging New Jersey’s life sciences companies, the New Jersey Economic Development Authority (EDA) has launched its inaugural group of Executives-in-Residence. These highly-qualified life sciences executives mentor and advise emerging technology companies at the Commercialization Center for Innovative Technologies (CCIT), the EDA’s life sciences incubator. The Executive-in-Residence program was created in collaboration with BioNJ.
Philadelphia, PA - Innovation in New Jersey dates back to Einstein and Edison, but a new wave of discovery in life sciences is happening right now across the Garden State. At both the corporate and academic level, researchers throughout the state are tackling some of the industry’s biggest challenges. To showcase the state’s groundbreaking research, Choose New Jersey is launching a new concept at the New Jersey Pavilion this year: the BIO Innovation Theater.
Here is the complete schedule: http://bit.ly/1Qzf5oX
Mount Laurel, NJ - The NJ Tech Council 2015 CFO Awards Breakfast was recently held at the Forsgate Country Club in Monroe. Four awards were given by the Tech Council, a trade organization in the region supporting technology companies.
Trenton, NJ - New Jersey will showcase its business strengths in the life science industry to a global audience next week at the world’s largest biotechnology conference, BIO International, being held at the Philadelphia Convention Center on June 15-18.
Trenton, NJ - According to Melissa Orsen of the NJEDA, "
Philadelphia, PA - James C. Greenwood, president and CEO of the Biotechnology Industry Organization (BIO), is thrilled that the 2015 BIO International Convention is being held in Philadelphia. When he first joined the organization 10 years ago, the annual convention was on his home turf. Held at various US locations since that time, industry representatives from New Jersey, Delaware and Pennsylvania had been asking him: “When is BIO International coming back to the area?”
New Brunswick, NJ - According to Dean Paranicas, "The HealthCare Institute of New Jersey (HINJ) serves as a voice for the state’s life sciences community. The HINJ seeks to expand patient access to the most innovative biopharmaceuticals and medical devices and promote awareness of the industry’s impact on New Jersey’s quality of life and economic well-being."
Trenton, NJ - According to Debbie Hart of BioNJ, "The biotechnology industry in New Jersey continues to make significant strides and remains at the forefront of innovation. As reported in BioNJ’s industry study “Life Sciences in New Jersey,” in September 2014, there were 379 biotechnology companies operating in the state, up from 340 in 2012, representing an increase of 12 percent. New Jersey is presently ranked as the third largest biotech cluster in the country. This growth comes from new companies starting in New Jersey, companies relocating from other states and foreign-based companies establishing their US operations here."
Kenilworth, NJ - Merck announced that the company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for grazoprevir/elbasvir (100mg/50mg), an investigational once-daily, single tablet combination therapy for the treatment of adult patients with chronic hepatitis C genotypes (GT) 1, 4 or 6 infection. Within 60 days of submission, the FDA will determine whether it will accept for review Merck's application as filed. The company plans to submit additional license applications in the European Union and other markets by the end of 2015.
Trenton, NJ - Since arriving at the Commercialization Center for Innovative Technologies (CCIT) in North Brunswick just over a year ago, Aucta Pharmaceuticals has built a name for itself within New Jersey’s life sciences community. The company has already secured multiple sources of funding and its co-founder and Chief Executive Officer Dr. Shoufeng Li is highly regarded within the industry. The new drug product development company concentrates on novel and niche generic product development. In addition, Aucta Pharmaceutical offers proprietary technology focusing on poor water soluble compounds, controlled release dosage forms and compliance enhancing formulations.
Madison, NJ - The Medical Innovation Impact Index (MI3), a new method for evaluating the impact of regulation on medical innovation, has been developed at the Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s (FDU) Rothman Institute of Innovation and Entrepreneurship. The inaugural MI3 Alert pertains to new FDA (Food & Drug Administration) draft guidance documents and a Senate proposal for accelerating the approval of certain medical devices.
Princeton, NJ - According to Rose Huber, "The measles virus can cause serious disease in children by temporarily suppressing their immune systems. This vulnerability was previously thought to last a month or two, however, a new study shows that children may in fact live in the immunological shadow of measles for up to three years, leaving them highly susceptible to a host of other deadly diseases."
Sewell, NJ - In 1981, George and Lucy Malmberg decided they wanted to become entrepreneurs, so they purchased a bankrupt pharmacy in Sewell. Breaking even was not an easy task for the couple, but they were dedicated to making the business work by opening early and closing late.
Do not miss a single innovative moment and sign up for our newsletter!